AVATAMED

Chief Executive Officer Young K. Yun PhD

- Former Sr. Director of APAC Divisional GM at ThermoFisher
- Former Director of APAC Divsional GM at PerkinElmer
- Former Director of APAC/Japan GM of Caliper LS
- Former Director of International business at Argonaut Tech

Executive Life Science leader with 25 years' experience gained through leadership positions at start up, and global organizations. Consistently achieved significant business impact globally, leveraging international experience, leadership skills, creativity and human potential, strong market knowledge, strategic thinking..

Chief Medical Officer Pierce Chow MD

MBBS, FRCSE, M Med (Surgery), FAMS, PhD
- Professor and Course Director, Duke-NUS Medical School, Singapore
- Senior Consultant, Division of Surgery & Surgical Oncology, Singapore General Hospital and National Cancer Centre Singapore
- Senior Consultant, Department of Hepato-Pancreato- Biliary and Transplant Surgery, Singapore General Hospital

Prof Pierce Chow is senior consultant and Co-Director (Surgical) of the Comprehensive Liver Cancer Clinic at the National Cancer Centre Singapore and Senior Consultant Surgeon in HPB and Transplant Surgery at the Singapore General Hospital. He is concurrently Professor and Course Director at Duke- NUS Medical School Singapore.

Prof Chow leads collaborative multi-disciplinary research on intra-tumoral genomic, immunomic and metabolomic heterogeneity in HCC and their applications to precision medicine. He co-founded the Asia-Pacific Hepatocellular Carcinoma Trials Group in 1997 and has been the protocol chair of 7 prospective multi-national trials. In 2005, he led the multi-disciplinary research that developed BrachySil® (now OncoSil®) and the subsequent first-in-man trial. In 2012, the National Medical Research Council Singapore conferred him the National Outstanding Clinician-Scientist Award for improving clinical outcomes of patients with his research on Liver Cancer.

In 2016, Prof Chow was awarded the NMRC Translational-Clinical Research Grant for the National Flagship Program in Liver Cancer and launched the multi-national PLANET study (Precision Medicine in Liver Cancer Asia-Pacific Network). In 2017, he received additional funding from BMRC to develop the multi-institutional PuRPOSE Program to develop a patient-specific diagnostic and predictive platform to improve treatment of liver cancer.

Chief Science Officer Vinay Tergaonkar PhD

- Research director, IMCB, A*STAR
- Professor, NUS, Yong Loo Lin School of Medicine

Prof. Vinay Tergaonkar is an International Cancer Society (UICC) Fellow at Tufts University, Boston and a Leukemia and Lymphoma Society of America Fellow (2001-2004) and Special Fellow (2004-present) at the Salk Institute for Biological Studies, California. He serves on the Editorial Boards of several journals including Science Advances (American Association for the Advancement of Science), Molecular and Cellular Biology (The American Society for Microbiology), and Biochemical Journal (Portland Press). Work from his Lab received international recognition including the British Council Development Award (2014), the Premier’s Fellowship from the Government of South Australia (2015) and the University of Macau Distinguished Professorship (2019).

LEADERSHIP